Nantahala Capital Management LLC bought a new stake in shares of MiMedx Group, Inc (NASDAQ:MDXG - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 4,767,552 shares of the company's stock, valued at approximately $18,355,075. Nantahala Capital Management LLC owned 3.27% of MiMedx Group at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also bought and sold shares of the stock. Kemnay Advisory Services Inc. bought a new stake in MiMedx Group in the fourth quarter valued at approximately $48,000. Sunbelt Securities Inc. purchased a new stake in shares of MiMedx Group during the first quarter valued at approximately $42,000. Jain Global LLC purchased a new stake in shares of MiMedx Group during the fourth quarter valued at approximately $73,000. E Fund Management Co. Ltd. bought a new position in shares of MiMedx Group in the second quarter worth approximately $45,000. Finally, Virtu Financial LLC bought a new position in shares of MiMedx Group in the fourth quarter worth approximately $78,000. 79.15% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
A number of research firms recently commented on MDXG. Seaport Research Partners lowered shares of MiMedx Group to a "neutral" rating in a report on Monday, August 17th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $8.00 price target on shares of MiMedx Group in a research report on Monday, August 17th. Raymond James Financial set a $8.00 price objective on MiMedx Group in a report on Monday, August 17th. Wall Street Zen raised MiMedx Group from a "sell" rating to a "hold" rating in a research note on Saturday. Finally, Craig Hallum upped their target price on MiMedx Group from $6.00 to $8.00 and gave the company a "buy" rating in a report on Thursday. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, MiMedx Group presently has an average rating of "Moderate Buy" and an average price target of $8.57.
View Our Latest Analysis on MDXG
MiMedx Group Trading Down 0.2%
Shares of MDXG opened at $4.50 on Friday. The firm's 50-day moving average price is $4.18 and its 200-day moving average price is $4.09. The firm has a market capitalization of $655.92 million, a price-to-earnings ratio of 112.53 and a beta of 1.45. The company has a current ratio of 5.33, a quick ratio of 4.79 and a debt-to-equity ratio of 0.07. MiMedx Group, Inc has a 1-year low of $3.03 and a 1-year high of $7.97.
MiMedx Group (NASDAQ:MDXG - Get Free Report) last released its quarterly earnings results on Wednesday, July 29th. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.05). MiMedx Group had a net margin of 1.76% and a return on equity of 12.09%. The company had revenue of $64.36 million during the quarter, compared to the consensus estimate of $63.46 million. Sell-side analysts anticipate that MiMedx Group, Inc will post -0.1 EPS for the current year.
MiMedx Group Profile
(
Free Report)
MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company's core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx's product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.
MiMedx's principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider MiMedx Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiMedx Group wasn't on the list.
While MiMedx Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
